Grufity logo
Grufity logo
IPSC

IPSC - Century Therapeutics Inc Stock Price, Fair Value and News

$2.01+0.07 (+3.61%)
Market Closed as of 14 Sep 2026, 04:00 pm ET

IPSC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IPSC Price Action

Last 7 days

-4.7%

Last 30 days

4.7%

Last 90 days

-7.8%

Trailing 12 Months

302%

IPSC RSI Chart

IPSC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IPSC Valuation

Market Cap

364.0M

Price/Earnings (Trailing)

-3.32

Price/Sales (Trailing)

3.27

EV/EBITDA

83.39

Price/Free Cashflow

-4.13

IPSC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IPSC Fundamentals

IPSC Revenue

Revenue (TTM)

109.2M

Rev. Growth (Yr)

-100%

IPSC Earnings

Earnings (TTM)

-109.8M

Earnings Growth (Yr)

-6.17%

Earnings Growth (Qtr)

-59.62%

IPSC Profitability

EBT Margin

-8.84%

Return on Equity

-47.25%

Return on Assets

-38.25%

Free Cashflow Yield

-24.21%

IPSC Investor Care

Shares Dilution (1Y)

109.77%

Diluted EPS (TTM)

-0.93

IPSC Alerts

  • Losses in recent quarter
Revenue & Growth

How Century Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025114.9M114.1M113.3M109.2M
20241.4M2.0M2.7M6.6M
20235.9M4.6M2.5M2.2M
2022---5.2M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Century Therapeutics Inc

IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
 CEO
 WEBSITEcenturytx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES163

Century Therapeutics Inc Frequently Asked Questions

IPSC is the stock ticker symbol of Century Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Century Therapeutics Inc is 363.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, IPSC's PE ratio (Price to Earnings) is -3.32 and Price to Sales (PS) ratio is 3.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IPSC PE ratio will change depending on the future growth rate expectations of investors.